Trial intelligence / Profile preview

Single-dose SLV320 in congestive heart failure during right heart catheterization

2004-000442-21Phase 2Completed

Sponsor
Solvay Pharmaceuticals
Start
Jun 2005
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of derenofylline in heart failure (HF) (4 arms), sponsored by Solvay Pharmaceuticals. Primary endpoint: Maximum change from baseline in pulmonary capillary wedge pressure over first 12 hours on Day 1. Started Jun 2005; status: completed.

02

Drugs

derenofylline
03

Conditions

heart failure (HF)

Beyond the preview

Go deeper on 2004-000442-21.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-000442-21.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call